Minrin (Desmopressin Acetate)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers the insertion of aquaporin‑2 channels, allowing more water to be reabsorbed and urine to become more concentrated. In bleeding disorders, it stimulates endothelial release of von Willebrand factor and factor VIII, enhancing platelet adhesion and clot stability.

The appropriate dose of Minrin is determined by the prescribing clinician based on the patient’s condition, age, weight, renal function and response to therapy. Dosage regimens differ for endocrine versus haemostatic indications, and the prescriber will tailor the amount and frequency to achieve the desired clinical effect while minimizing risk.

Desmopressin is classified as a prescription‑only medication, and its safety in pregnancy or lactation has not been fully established. Healthcare providers should weigh potential benefits against possible risks, consider alternative therapies, and discuss any concerns with the patient before initiating treatment.

To request Minrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Minrin (desmopressin) is a synthetic vasopressin analog with high selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic drugs, it provides more predictable water reabsorption and is also approved for haemostatic use, which many alternative agents lack.

Minrin should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution, as temperature excursions can affect potency and sterility.

Minrin is supplied as an injectable solution and can be given intramuscularly, intravenously or subcutaneously, depending on the clinical indication and prescriber’s preference. The route, dose and administration schedule are determined by the treating physician and should follow aseptic technique and local prescribing guidelines.

The most critical safety concerns with Minrin involve severe hyponatraemia, which can lead to seizures, cerebral oedema, or hyponatraemic encephalopathy. Water intoxication and thrombotic complications are also serious risks, particularly in patients with underlying cardiac or renal disease. Prompt monitoring of serum sodium and fluid balance is essential.

Minrin is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hyponatraemia, and in individuals with severe renal impairment where water clearance is compromised. Caution is also advised for patients with a history of thromboembolic disease or uncontrolled hypertension.